key: cord-0951647-2v7rtdx6
authors: Morales Cerchiaro, Á.P.; Carrascal, M. L.; Arhip, L.; Velasco, C.; Bretón, I.; Motilla, M.; Serrano, C.; Calvo, C.; González, L.; Muñoz, D.; Camblor, M.; Frias, L.; Cuerda, C.
title: Recovery program for critically ill Covid-19 patients after 6 weeks of follow-up from discharge
date: 2021-12-31
journal: Clinical Nutrition ESPEN
DOI: 10.1016/j.clnesp.2021.09.632
sha: a2a700cfee0c9c71ccc94a493e4b471cd2fa90c5
doc_id: 951647
cord_uid: 2v7rtdx6

nan

Rationale: It is stated that the administration of high doses of intravenous (IV) vitamin C (VC), which has been the subject of discussion since the beginning of the COVID-19 pandemic, may be associated with the cytokine storm observed during infection and increasing in parallel with the severity of the disease, and immunosuppressive effects may be observed. In this study, it was aimed to examine the relationship between IV VC and survival in patients with COVID-19 infection hospitalized in the intensive care unit (ICU). Methods: This retrospective and cross-sectional study was carried out using data from 130 patients (68 male) treated with the diagnosis of COVID-19 in the ICU of Biruni University Hospital (Istanbul). From management system and the archive files of the patients; anamnesis and disease history collected. According to the patient's prognosis, IV VC was administered as 2-12 g/day in the ICU and biochemical parameters data were evaluated. Results: Intravenous VC treatment was given to 53 (32 men) of 130 COVID-19 patients with a median age of 73 (IQR: 26-96) years. Length of hospitalization was higher (12 days vs. 6 days, p<0.05) in patients managed with VC than in those without. The administration of VC was associated with a significant increase in C-reactive protein, hematocrit and hemoglobin levels were higher in patients under 65 years of age who were received IV VC treatment; in patients over 65 years of age, sodium was found to be higher than those who were not received (p<0.05). 38 (68.4% men) of the patients who were given IV VC treatment and 46 (41.3% men) of those who were not given exitus. It was observed that the survival ratio of men given IV VC treatment was lower than that of women (p¼0.034). Conclusion: This study showed that administrated VC did not improve the survival and length of hospitalization. More large-scale studies are required to further assess the role of VC in the treatment of COVID-19. Rationale: To assess the evolution of patients with severe pneumonia due to COVID19 who have required intensive care(ICU). Methods: Prospective observational study.212 ICU patients were included from March 16-2020, to June 25-2021.Clinical evaluation(including nutritional, functional, strength, dependency and quality of life assessment) was carried out during hospitalization and by telephone 6 weeks after discharge. Age, sex, hospital stay, ICU stay, weight, height, weight loss, BMI, dietaryintake estimation, Barthelscale, SARC-Ftest and the EQ-5D-5Lquestionnaire, nutritional treatment and therapeutic compliance were collected. The results are expressed as mean±SD and percentages(IBM-SPSS21.0). Results: 212 patients aged 58.4±12.4 years were included, 63.7%male, weight at discharge 76.6±16.1kg, BMI 26.1 ± 7.4kg / m2. Total stay 55.1 ± 38.1 days, ICU stay 30.2±28.0 days and 61.9% needed intubation. Mean percentage of weight loss at hospital discharge was 12.2±7.3%, 9.3%had dysphagia and 74.7%had an oral nutritional supplement prescribed at discharge.

Conclusion: Patients gained weight, improved intake, reduced the risk of sarcopenia, and perceived a significantly better quality of life after 6 weeks of hospital discharge. There was a good compliance with the specific nutritional therapy that can be important in the recovery of these patients. Rationale: Progressive familial intrahepatic cholestasis (PFIC) is a group of genetic diseases affecting the hepatocellular transport and bile formation. In PFIC3 there is a defect in the ABCB4 gene, which leads to impaired biliary phospholipid secretion, damaged hepatocytes and bile ducts, and heterogeneous clinical presentation. Growth impairment is often described in children with cholestatic liver diseases. The aim of our study was to assess the nutritional status in patients with PFIC3. Methods: We present a single-centre retrospective study of patients with genetically confirmed PFIC3. Nutritional assessment at the time of diagnosis included anthropometry, biochemical and clinical methods. Age and gender-specific growth charts for height, weight and Body Mass Index (BMI) were used.

Results: Ten patients (6 boys and 4 girls) with PFIC3 diagnosed at the age between 1 and 17 years were included. The age of initial presentation was between 5 months and 14 years, all patients had hepatosplenomegaly, the majority (6/10) had pruritus. On follow-up, two children are stable with good liver function, five children have progressive liver disease, and three children are successfully transplanted. The anthropometric parameters at the time of diagnosis showed that three patients were below the 5 th centile for height-for-age and two patients were below the 5 th centile for weightfor-age. Two patients from all 8 aged >2 years at diagnosis showed underweight with BMI less than the 5 th centile for age. The levels of vitamins and microelements were not assessed in all patients. However, moderate fatsoluble vitamin deficiencies and anaemia were detected in some patients. Conclusion: Children with PFIC often present with nutritional deficiencies and growth impairment. More parameters have to be evaluated in patients with PFIC3 to better understand pathogenesis of growth failure in this disease. Nutritional assessment and support are essential to improve patient survival and quality of life.

Nutritional evaluation of children with chronic cholestatic disease

197. 2. Mandato C, Di Nuzzi A, Vajro P. Nutrition and Liver Disease

Hypertension status was ascertained according to selfreported medications, systolic blood pressure (SBP) 140 mmHg or diastolic blood pressure (DBP) 90 mmHg. Serum TMAO, choline and betaine were determined by HPLC-MS/MS. Logistic regressions and multiple linear regressions were used to estimate the association between serum TMAO, choline, betaine with odds of hypertension and blood pressure (BP) levels. Results: The medians (IQRs) of serum TMAO

The Gut Microbial Metabolite Trimethylamine N-Oxide and Hypertension Risk: A Systematic Review and Dose-Response Meta-analysis

Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and